Grant opportunity
Hereditary Hemorrhagic Telangiectasia (HHT) Center
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
- Funder
- Health Resources and Services Administration / Department of Health and Human Services
- Closes 2026-07-10
- Closes 2026-07-10: Jul 10, 2026
- Award
- up to USD 2,900,000
- Applicant
- Organizations and institutions
- Discipline
- Health and Biomedical Sciences
- Region
- Asia
- Posted
- Jun 8, 2026
Call summary
Overview
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Who can apply
"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
What it supports
- Health and Biomedical Sciences
- Asia
- Opportunity number: HRSA-26-092.
Funding and duration
- up to USD 2,900,000
Closes 2026-07-10
Closes 2026-07-10: Jul 10, 2026
How to apply
Use the official Grants.gov listing for the application package, attachments, forms and agency-specific instructions. Submit by 2026-07-10 unless the agency updates the official listing.
Call details
Source-based overview
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes. Eligibility: "Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. Opportunity number: HRSA-26-092. Closing date: 2026-07-10. Funding: up to USD 2,900,000.
Eligibility
"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
Funding and benefits
up to USD 2,900,000
Themes and supported activities
Health and Biomedical Sciences
Asia
Opportunity number: HRSA-26-092.
Deadline and timeline
Closes 2026-07-10: Closes 2026-07-10: Jul 10, 2026.
Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.
How to apply
Use the official Grants.gov listing for the application package, attachments, forms and agency-specific instructions. Submit by 2026-07-10 unless the agency updates the official listing.
Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.